Group 1 ITI Consensus Report: The role of bone dimensions and soft tissue augmentation procedures on the stability of clinical, radiographic, and patient-reported outcomes of implant treatment.

aesthetics bone augmentation dental implant evidence-based dentistry patient-reported outcome measures soft tissue augmentation surgical techniques systematic review

Journal

Clinical oral implants research
ISSN: 1600-0501
Titre abrégé: Clin Oral Implants Res
Pays: Denmark
ID NLM: 9105713

Informations de publication

Date de publication:
Sep 2023
Historique:
revised: 20 07 2023
received: 25 05 2023
accepted: 20 07 2023
medline: 23 10 2023
pubmed: 26 9 2023
entrez: 26 9 2023
Statut: ppublish

Résumé

The aims of Working Group 1 were to address the role (i) of the buccolingual bone dimensions after implant placement in healed alveolar ridge sites on the occurrence of biologic and aesthetic complications, and (ii) of soft tissue augmentation (STA) on the stability of clinical, radiographic, and patient-related outcomes of implant treatments. Two systematic reviews were prepared in advance of the Consensus Conference and were discussed among the participants of Group 1. Consensus statements, clinical recommendations, recommendations for future research, and reflections on patient perspectives were based on structured group discussions until consensus was reached among the entire group of experts. The statements were then presented and accepted following further discussion and modifications as required by the plenary. Dimensional changes of the alveolar ridge occurred after implant placement in healed sites, and a reduction in buccal bone wall thickness (BBW) of 0.3 to 1.8 mm was observed. In healed sites with a BBW of <1.5 mm after implant placement, increased vertical bone loss, and less favorable clinical and radiographic outcomes were demonstrated. Implants with buccal dehiscence defects undergoing simultaneous guided bone regeneration, showed less vertical bone loss, and more favorable clinical and radiographic outcomes, compared to non-augmented dehiscence defects during initial healing. At healthy single implant sites, probing depths, bleeding and plaque scores, and interproximal bone levels evaluated at 1 year, remained stable for up to 5 years, with or without STA. When single implant sites were augmented with connective tissue grafts, either for soft tissue phenotype modification or buccal soft tissue dehiscence, stable levels of the soft tissue margin, and stable or even increased soft tissue thickness and/or width of keratinized mucosa could be observed from 1 to 5 years. In contrast, non-augmented sites were more prone to show apical migration of the soft tissue margin in the long-term. Favorable aesthetic and patient-reported outcomes after STA were documented to be stable from 1 to 5 years. It is concluded that dimensional changes of the alveolar ridge occur after implant placement in healed sites and that sites with a thin BBW after implant placement are prone to exhibit less favorable clinical and radiographic outcomes. In addition, it is concluded that STA can provide stable clinical, radiographic, aesthetic, and patient-reported outcomes in the medium and long-term.

Identifiants

pubmed: 37750519
doi: 10.1111/clr.14154
doi:

Substances chimiques

Dental Implants 0

Types de publication

Journal Article

Langues

eng

Pagination

43-49

Informations de copyright

© 2023 The Authors. Clinical Oral Implants Research published by John Wiley & Sons Ltd.

Auteurs

Simon S Jensen (SS)

Research Area Oral Surgery, Section for Oral Biology and Immunopathology, Department of Odontology, University of Copenhagen, Copenhagen, Denmark.
Department of Oral & Maxillfacial Surgery, Centre for Head and Orthopedics, Copenhagen University Hospital, Copenhagen, Denmark.

Tara Aghaloo (T)

Oral and Maxillofacial Surgery, UCLA School of Dentistry, Los Angeles, California, USA.

Ronald E Jung (RE)

Center of Dental Medicine, Clinic of Reconstructive Dentistry, University of Zürich, Zürich, Switzerland.

Kristina Bertl (K)

Department of Periodontology, Dental Clinic, Faculty of Medicine, Sigmund Freud University, Vienna, Austria.
Department of Periodontology, Faculty of Odontology, University of Malmö, Malmö, Sweden.

Daniel Buser (D)

School of Dental Medicine, University of Bern, Bern, Switzerland.
Private Practice, Bern, Switzerland.

Vivianne Chappuis (V)

Department of Oral Surgery and Stomatology, Division of Oral Diagnostic Sciences, University of Bern, Bern, Switzerland.

Luca de Stavola (L)

Department of Implantology, School of Dentistry, University of Padua, Padua, Italy.
Private Practice, Padua, Italy.

Alberto Monje (A)

Department of Periodontology, Universitat Internacional de Catalunya, Barcelona, Spain.
Department of Periodontology, The University of Michigan, Ann Arbor, Michigan, USA.
Department of Periodontology, ZMK University of Bern, Bern, Switzerland.
Private Practice, Badajoz, Spain.

Alberto Pispero (A)

Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy.

Andrea Roccuzzo (A)

Department of Periodontology, School of Dental Medicine, University of Bern, Bern, Switzerland.

Shakeel Shahdad (S)

Department of Restorative Dentistry, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, London, UK.

Martina Stefanini (M)

Periodontology, School of Dentistry, Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.

Lorenzo Tavelli (L)

Department of Oral Medicine, Infection, and Immunology, Division of Periodontology, Harvard School of Dental Medicine, Boston, Massachusetts, USA.

Hom-Lay Wang (HL)

Department of Periodontics and Oral Medicine, The University of Michigan, School of Dentistry, Ann Arbor, Michigan, USA.

Giovanni Zucchelli (G)

Periodontology, School of Dentistry, Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.
Department of Periodontics and Oral Medicine, School of Dentistry, University of Michigan, Ann Arbor, Michigan, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH